Afuco™ Anti-Human MMP9 ADCC Recombinant Antibody (GS-5745), ADCC Enhanced (CAT#: AFC-513CL)

Anti-MMP9 ADCC Enhanced Antibody (GS-5745) is an ADCC enhanced antibody produced by our Afuco™ platform. GS-5745 is a monoclonal antibody that inhibits matrix metalloproteinase 9 (MMP9), an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. Inhibiting MMP9 is expected to block paracrine signaling and metastasis and to alter the immune environment within the tumor. Preliminary safety data demonstrate a manageable safety profile for GS-5745 alone and in combination with chemotherapy. The study has been expanded to enroll additional subjects with pancreatic and esophagogastric cancer to identify potential pharmacodynamic and predictive biomarkers of response.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Efficacy endpoints.

Figure 1 Efficacy endpoints.

The proportion of patients achieving [A] EBS clinical remission, [B] MCS response, [C] endoscopic response, and [D] mucosal healing at Week 8. [E] Change from baseline in partial MCS over time. [A–D] Values indicate percentage of patients per treatment group achieving response. Error bars indicate upper and lower 95% confidence interval. [E] Data represented as mean with error bars indicating SD. EBS clinical remission defined as endoscopic subscore of 0 or 1, rectal bleeding score of 0, and ≥1-point decrease in stool frequency to achieve a subscore of 0 or 1; MCS response defined as reduction of ≥3 points and at least 30% from baseline with decrease in rectal bleeding subscore of ≥1 point or an absolute rectal bleeding subscore of 0 or 1; endoscopic response defined as endoscopic subscore of 0 or 1; mucosal healing defined as elimination of ulcers/erosion, elimination of crypt destruction, elimination of intraepithelial neutrophils, elimination of lamina propria neutrophils, and reduction in lamina propria chronic inflammatory cells to at most a mild increase. Partial MCS comprised subscores from rectal bleeding, stool frequency, and PGA. aPatients with mucosal healing at baseline were excluded from the analysis. EBS, endoscopy/bleeding/stool; MCS, Mayo clinical score; PGA, physician's global assessment; Q2W, every 2 weeks; QW, weekly; SD, standard deviation.

Sandborn, W. J., Bhandari, B. R., Randall, C., Younes, Z. H., Romanczyk, T., Xin, Y., ... & Sundy, J. S. (2018). Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. Journal of Crohn's and Colitis,12(9), 1021-1029.

Figure 2 Mean plasma concentration vs time curves for andecaliximab Q2W and QW.

Figure 2 Mean plasma concentration vs time curves for andecaliximab Q2W and QW.

Error bars indicate SD. Arrows indicate drug administration for Q2W dosing. All PK samples were collected before dosing on respective treatment days. For the 150 mg Q2W group, the Week 8 concentration was determined 2 weeks following the previous dose, whereas Week 1 and Week 5 concentrations were determined 1 week following the previous dose. PK, pharmacokinetic; Q2W, every 2 weeks; QW, weekly; SD, standard deviation.

Sandborn, W. J., Bhandari, B. R., Randall, C., Younes, Z. H., Romanczyk, T., Xin, Y., ... & Sundy, J. S. (2018). Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. Journal of Crohn's and Colitis,12(9), 1021-1029.

Figure 3 GS-5745 demonstrate noncompetitive inhibition of MMP9: Antibody-mediated inhibition of MMP9 activity was assessed at multiple concentrations of substrate (a fluorogenic peptide).

Figure 3 GS-5745 demonstrate noncompetitive inhibition of MMP9: Antibody-mediated inhibition of MMP9 activity was assessed at multiple concentrations of substrate (a fluorogenic peptide).

Marshall, D. C., Lyman, S. K., McCauley, S., Kovalenko, M., Spangler, R., Liu, C., ... & Mikels-Vigdal, A. (2015). Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer. PloS one,10(5), e0127063.


Specifications

  • Host Species
  • Humanized
  • Derivation
  • Humanized
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Related Disease
  • Solid Tumors

Product Property

  • Purity
  • >95%, by SDS-PAGE with Coomassie Brilliant Blue staining
  • Storage
  • ≤1 year at -20°C.

Target

  • Alternative Names
  • MMP9; matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); GELB; CLG4B; MMP-9; MANDP2; matrix metalloproteinase-9; type V collagenase; macrophage gelatinase; matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)

Related Resources

  • Related Signaling Pathways

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "MMP9"

Humanized Antibody

CAT Product Name Application Type
TAB-533CL Anti-Human MMP9 Recombinant Antibody (GS-5745) WB, Inhib Antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0717MZ Chicken Anti-MMP9 Polyclonal IgY WB Chicken antibody

Blocking Antibody

CAT Product Name Application Type
NEUT-1748CQ Recombinant Mouse Anti-MMP9 Antibody (VMC204) Inhib, IHC-Fr, IP, IHC-P, WB, IHC, ICC IgG1

Chimeric Antibody

CAT Product Name Application Type
TAB-002ML Anti-Human MMP9 Recombinant Antibody (Andecaliximab) ELISA, IHC, FC, IP, IF, FuncS IgG4, κ

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-002ML Afuco™ Anti-MMP9 ADCC Recombinant Antibody (Andecaliximab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for AFC-513CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare